Starpharma (ASX: SPL) Soars 70% on Genentech Deal

Starpharma Lands Genentech Collaboration

Starpharma (ASX: SPL) has caught investor attention with a stunning 70 percent share price surge after unveiling a collaboration with global biotech giant Genentech. At the heart of the deal is Starpharma’s DEP platform, which uses dendrimers—tiny, tree-like molecules designed to carry cancer drugs more effectively through the body. By “loading” Genentech’s therapies onto these carriers, the aim is to improve how long the drugs remain active and how precisely they reach tumour tissue, potentially transforming treatment outcomes.

For a company that generated USD 29 million in revenue last year, the upfront USD 5.5 million payment is meaningful, representing around 20 percent of its annual sales. Beyond the financial boost, the partnership places Starpharma in the global spotlight at a time when investors are searching for biotech platforms with scalable applications rather than one-off drugs.

The excitement is clear, but the bigger question for investors is whether this deal marks the start of a long-term growth story or simply a short-lived spike in sentiment.

What are the Best Biotech ASX Stocks to invest in right now?

Check our buy/sell tips

Starpharma’s DEP Platform Targets Smarter Cancer Treatments With Early Clinical Validation

Starpharma is an Australian biotechnology company focused on developing and commercialising medicines through its proprietary DEP drug delivery platform. The company’s mission is to improve patient outcomes in cancer treatment by enhancing the way therapies are delivered in the body. The DEP platform is built on dendrimers, which are highly branched nanoscale molecules that act as carriers for drugs. 

This structure allows medicines to dissolve and circulate more effectively, while directing a higher concentration to tumours rather than healthy tissue, addressing a common limitation in oncology. To date, more than 350 patients have already been treated with DEP-based therapies in clinical trials, providing early validation of the platform’s potential to improve efficacy and reduce side effects.

Genentech Partnership Propels Starpharma’s DEP Platform Onto the Global Oncology Stage

This announcement is significant for investors because Genentech is one of the most respected names in oncology and is committing to Starpharma’s DEP platform after three years of collaboration. The agreement extends the reach of DEP beyond Starpharma’s internal pipeline by embedding it into Genentech’s oncology programs, potentially across multiple drugs and targets. 

Importantly, the partnership reinforces Starpharma’s strategy of forming high-impact alliances to commercialise DEP on a global scale. By outsourcing development and commercialisation to Genentech, the company can focus on its core strength of platform innovation while gaining exposure to large oncology markets it could not pursue independently.

The investor’s takeaway

Starpharma offers an innovative drug delivery platform that has the potential to be integrated across a wide range of therapies if clinical programs succeed. This creates a pathway for the company’s technology to play a role in multiple drug classes and with several partners. At the same time, there are clear risks to consider. Partnerships such as the agreement with Genentech place control of development and commercialisation largely in the hands of its collaborators, leaving Starpharma dependent on their execution.

From a financial perspective, the company remains pre-profit and reliant on external partnerships for funding. While the upfront payment provides near-term support, delays in achieving future milestones could place pressure on the balance sheet.